NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage

NRx Pharmaceuticals commenced sales of its FDA-approved preservative-free ketamine this week through a 17-person veteran sales force covering approximately 80% of the U.S. market. The product uses blow-fill-seal (BFS) technology in a needle-free vial, addressing a ketamine shortage since 2018 and eliminating the controversial preservative benzethonium chloride. The company expects gross and net margins exceeding 50% and has contracted with German suppliers to expand manufacturing capacity in South Carolina.